SEC Form 4 · accession 0001209191-15-008138
CLEVELAND BIOLABS INC · CBLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elena Kasimova
Director
Period of report
Jan 27, 2015
Accepted (ET)
Feb 2, 2015 · 12:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001318641
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $4.80 | Jan 27, 2015 | A | 750 | A | — | Jan 26, 2025 | Common Stock | 750 | 750 | D |
Explanation of responses
- F1As adjusted for 20-to-1 reverse stock split, effective January 28, 2015.
- F2The option became exercisable with respect to 33.33% of the total shares on January 27, 2015, and will become exercisable for 66.67% of the total shares on January 27, 2016, and 100% of the total shares on January 27, 2017.